Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.


Fenretinide (4HPR), a nontoxic analog of ATRA, has been investigated in various malignancies but not in multiple myeloma (MM), a plasma cell malignancy associated with induction of osteolytic bone disease. Here we show that 4HPR induces apoptosis through increased level of ROS and activation of caspase-8, 9 and 3, and inhibits growth of several MM cell… (More)
DOI: 10.1016/j.canlet.2009.04.022


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics